Cargos activos de Ping Zhu
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Director/Miembro de la Junta | - | - |
| Director Técnico/Científico/I+D | 01/08/2021 | - | |
| Presidente | 01/08/2021 | - | |
| Corporate Officer/Principal | 01/01/2012 | 30/08/2021 |
Historial de carrera de Ping Zhu
Formación de Ping Zhu.
| Shanghai Second Medical University | Undergraduate Degree |
| University of Karlsruhe | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 2 |
| China | 2 |
| Alemania | 2 |
Operativa
| Director/Board Member | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
Sectorial
| Consumer Services | 3 |
| Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
- Bolsa de valores
- Insiders
- Ping Zhu
- Experiencia
